相关实验视频
Updated: Feb 16, 2026

Molecular Evolution of the Tre Recombinase
Published on: May 29, 2008
萨尔科马的内瘤异质性和克隆进化:治疗耐药性的分子,细胞和功能驱动因素
Thomas G P Grünewald1, Ina Oehme2, Johanna Wagner3
1Division of Translational Pediatric Sarcoma Research, German Cancer Research Center (DKFZ), Heidelberg, Germany; Hopp Children's Cancer Center Heidelberg (KiTZ), Heidelberg, Germany; National Center for Tumor Diseases (NCT), NCT Heidelberg, a partnership between DKFZ and Heidelberg University Hospital, Heidelberg, Germany; German Cancer Consortium (DKTK), Core Center Heidelberg, Heidelberg, Germany; Institute of Pathology, Heidelberg University Hospital, Heidelberg, Germany.
本综述探讨了使用先进的奥米克的瘤内异质性 (ITH). 了解ITH复杂性是改善肉瘤治疗和患者治疗结果的关键.
科学领域:
- 在瘤学瘤学.
- 基因组学就是基因组学.
- 分子生物学分子生物学
背景情况:
- 瘤是一种罕见的中瘤,具有高度多样性和内异质性 (ITH),具有临床挑战.
- 肉瘤ITH提供了一个研究分子基础和临床结果相关性的模型.
- 单细胞和空间奥米克技术为瘤架构提供了高分辨率的洞察力.
研究的目的:
- 审查了解瘤瘤内部异质性 (ITH) 的最新进展.
- 要突出ITH是如何推动肉瘤进展和治疗耐药性的.
- 讨论ITH建模和评估患者特异性反应的新方法.
主要方法:
- 关于瘤ITH的最新科学文献的综述.
- 专注于五种代表性瘤实体:骨髓瘤,非分化的脂质瘤,尤文瘤,阴膜瘤和膜骨髓瘤.
- 整合单细胞和空间奥米克数据以说明ITH.
主要成果:
- 克隆性/亚克隆性变化,瘤基因活性和细胞可塑性有助于肉瘤的进展.
- 复杂的内生态系统和ITH影响治疗耐药性.
- 新技术使得 Sarcomas 的功能多样性的高级建模和评估成为可能.
结论:
- 瘤内部异质性是肉瘤进展和治疗耐药性的关键因素.
- 先进的奥米克技术正在彻底改变对肉瘤的研究.
- 未来的研究方向集中在ITH对个性化肉瘤治疗的临床影响上.
更多相关视频
09:09Laser Capture Microdissection of Glioma Subregions for Spatial and Molecular Characterization of Intratumoral Heterogeneity, Oncostreams, and Invasion
Published on: April 12, 2020
08:59Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down
Published on: December 11, 2017
相关概念视频
The Evidence for Evolution
Convergent Evolution
Genome Size and the Evolution of New Genes
Eukaryotic Evolution
Contrary to the endosymbiont theory, the eukaryote-first hypothesis proposes that the simpler prokaryotic and...
Synteny and Evolution
Around 80 million years ago, the human and mice lineages diverged from the common ancestor. During the course of evolution, the ancestral...
T Cell Activation and Clonal Selection
Naive T cells that have not yet encountered an antigen express two primary CD...